In a patient with metastatic ER/PR‑positive, HER2‑positive (3+) breast cancer who progressed after docetaxel‑carboplatin chemotherapy and adjuvant pertuzumab plus trastuzumab, what is the next recommended treatment?

Trastuzumab Deruxtecan (T-DXd) is the next recommended treatment for this patient.

For a patient with ER/PR-positive, HER2-positive (3+) metastatic breast cancer who progressed after adjuvant docetaxel-carboplatin and pertuzumab/trastuzumab, trastuzumab deruxtecan should be the second-line therapy 1, 2.

Treatment Rationale

Since this patient received pertuzumab and trastuzumab in the adjuvant setting and progressed to metastatic disease, they should follow second-line treatment recommendations rather than first-line, as the progression occurred after completing adjuvant HER2-targeted therapy 3.

Why Trastuzumab Deruxtecan?

The 2021 ESMO guidelines explicitly state that trastuzumab deruxtecan is the preferred second-line therapy after progression on a taxane and trastuzumab 1. This represents the most recent high-quality guideline evidence (2021) compared to the older ASCO 2018 guidelines that recommended T-DM1 as second-line 3. The updated 2022 ASCO guideline reinforces this, stating that if a patient's HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy (and the patient has not received T-DXd), clinicians should recommend T-DXd as second-line treatment 2.

Alternative if T-DXd Unavailable

• T-DM1 (trastuzumab emtansine) remains a second-line option when trastuzumab deruxtecan is not available 1
• T-DM1 has high-quality evidence (EMILIA trial) showing improved PFS and OS compared to lapatinib plus capecitabine 4

Special Consideration: Brain Metastases

If this patient has brain metastases, tucatinib plus capecitabine plus trastuzumab may be considered as an alternative second-line option, as it demonstrated specific efficacy in patients with CNS involvement 1, 5.

Hormone Receptor-Positive Disease Management

Given the ER/PR-positive status, after completing chemotherapy cycles with T-DXd (typically 4-6 months or until maximal response), endocrine therapy may be added to continued HER2-targeted therapy 3. Options include:

• Aromatase inhibitor (AI) with ovarian function suppression if premenopausal
• AI alone if postmenopausal

However, the majority of patients with HER2-positive disease should receive HER2-targeted therapy plus chemotherapy as the backbone, with endocrine therapy as an adjunct 3.

Treatment Sequencing Algorithm

Second-line (Current situation):

1. Preferred: Trastuzumab deruxtecan
2. If T-DXd unavailable: T-DM1
3. If brain metastases present: Consider tucatinib + capecitabine + trastuzumab

Third-line (after T-DXd progression):

• Tucatinib + capecitabine + trastuzumab 1
• T-DM1 (if not previously used) 1

Fourth-line and beyond:

• Lapatinib + capecitabine 1
• Trastuzumab + chemotherapy combinations 1
• Neratinib + capecitabine (FDA approved, not EMA) 1
• Endocrine therapy + trastuzumab or lapatinib (for selected HR-positive cases with low disease burden) 3

Critical Monitoring

• Cardiac function: Assess LVEF before starting and every 12 weeks during treatment 3
• Interstitial lung disease (ILD): T-DXd carries a risk of ILD; monitor for dyspnea, cough, and fever 1
• Diarrhea management: Common with HER2-targeted therapies, particularly tucatinib combinations 5

Common Pitfall to Avoid

Do not restart first-line therapy (pertuzumab + trastuzumab + taxane) in this patient. Since they progressed after adjuvant pertuzumab/trastuzumab, they have already been exposed to dual HER2 blockade and should move to second-line options 3. The key principle is continued HER2 blockade beyond progression with a different mechanism of action 1.